Open Accessibility Menu

Clinical Trial Information

A phase 1, randomized, double-blind, placebo-controlled dosage escalation trial to evaluate the safety and immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted in HIV-uninfected, healthy adult volunteers

Study Details

This is a phase 1 first-in-human clinical trial to assess the safety, tolerability, and immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted, in up to 48 healthy adult HIV-negative volunteers.

Primary Sponsor:

International AIDS Vaccine Initiative

Prinicipal Investigator:

David Diemert, MD/Medicine

Contact Phone:

(202) 994-8976
A phase 1, randomized, double-blind, placebo-controlled dosage escalation trial to evaluate the safety and immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted in HIV-uninfected, healthy adult volunteers

Interested in More Information

  • Please enter your first name.
  • Please enter your last name.
  • This isn't a valid email address.
    Please enter your email address.
  • This isn't a valid phone number.
    Please enter your phone number.
    You entered an invalid number.
  • Please enter your address.
  • Please enter your city.
  • Please enter your state.
  • Please enter your zip code.
  • (All Uppercase. No Spaces)